Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 1672 · · 10 pages · English
Summary by 6ix AI
It reports on the movements in authorized and registered share capital, confirming a total authorized share capital at the end of the month. The document also includes details on issued shares, treasury shares, and public float sufficiency confirmation. The increase in issued shares during the month is noted, along with the status of treasury shares.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Ascletis Pharma
- Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
- Interim Report 2026
- Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
- Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
- Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
Later from Ascletis Pharma
- Next Day Disclosure Return
- Voluntary announcement - ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline for the treatment of obesity
- Voluntary announcement - ascletis' strategic partner sagimet announces first patient dosed in phase iii U.S. clinical trial of denifanstat (ASC40) for moderate to severe acne
Follow Ascletis Pharma into a list and get an email when it puts out news.
Follow Ascletis Pharma